Summary. Twelve hour metabolic rhythms have been determined in two groups of subjects during combined therapy with a sulphonylurea and phenformin 50 mg twice daily. Subjects with clinical evidence of complications of diabetes showed greater abnormalities in concentrations of blood intermediary metabolites than a group of subjects without complications despite similar mean blood glucose concentrations in the two groups (7.6 mmol/1 with complications; 7.3 mmol/1 without complications). Mean blood lactate (1.93 mmol/1 v 1.39 mmol/l), alanine (0.56 mmol/1 v 0.43 mmol/1), total blood ketone bodies (0.20mmol/l v 0.14mmol/1) and several other intermediary metabolites and their ratios were significantly higher in the group with diabetic complications. It is suggested that the differences between the two groups may arise from impaired disposal of phenformin leading to higher blood concentrations in the group with diabetic complications, despite normal liver function tests and plasma creatinine concentration. It is probable that this accumulation of phenformin results in more pronounced effect upon blood glucose and other intermediary metabolites. Thus, the metabolic abnormalities previously reported in patients treated by phenformin alone are also present during combined sulphonylurea and phenformin therapy, and in the presence of diabetic microangiopathy these abnormalities are accentuated.
Elevated concentrations of blood lactate and pyruvate occur in both the fasting state and during oral glucose tolerance tests in maturity-onset diabetics given phenformin [1, 2] . Similarly in patients treated with phenformin 50 mg twice daily the diurnal profiles of blood lactate and pyruvate were significantly elevated when compared with sulphonylurea therapy in the same subjects [3] . These subjects also showed significant elevations in blood total ketone bodies, glycerol, alanine, lactate/pyruvate ratio, and 3-hydroxybutyrate/acetoacetate ratio during phenformin therapy [3] . It is of obvious importance to see whether these abnormalities persist when phenformin is used in conjunction with a sulphonylurea.
In addition, in view of the association between phenformin therapy and lactic acidosis [4, 5, 6] it is important to identify groups of patients in whom these abnormalities are accentuated.
We have, therefore, investigated two groups of maturity-onset diabetics with and without diabetic complications during combined sulphonylurea and phenformin therapy by measurement of blood concentrations of intermediary metabolites and hormones over a 12 h period.
Materials and Methods
Twelve patients with maturity-onset diabetes of greater than two years duration were studied. At the time of study all patients had been taking a sulphonylurea and phenformin sustained release capsules (50 mg twice daily) for more than twelve months. None had evidence of hepatic disease as assessed by routine liver fun.ction tests and plasma creatinine was within the normal range in all patients. The twelve patients consisted of two groups of six subjects. In the first group, patients had no evidence of complications of diabetes while in the second group all patients had evidence of diabetic microangiopathy as assessed by clinical examination and ophthalmoscopy. Details of the patients and their therapy are shown in Table 1 .
Each study lasted 12 h. After an overnight fast an indwelling intravenous cannula was inserted into an antecubital vein at 0800 h. Following fasting samples at 0825 h and 0830 h breakfast was eaten. Blood samples were taken half-hourly until 2000 h and lunch was eaten at 1200 h, dinner at 1800 h, and snacks at 1005 h O012-186X/78/0014/0389/$01.40 alanine, were assayed in the perchloric acid extract by modified, automated, enzymic fluorimetric methods [7] . "Total" ketone bodies refers to the sum of 3-hydroxybutyrate and acetoacetate which were determined manually by enzymic methods [8] . Plasma NEFA were assayed by a radiocobalt method [9] and serum insulin and growth hormone (HGH) by double antibody radioimmunoassay [10, 11] .
Results are given as mean + standard error of the mean (SEM). Significant differences between fasting concentrations and at individual times throughout the 12 h have been assessed by Student's unpaired t-test. For an individual patient the 24 values over the 12 h for a metabolite or hormone have been averaged and this is referred to as the 12 h mean concentration of a metabolite or hormone. Significant differences over the whole of the 12 h period have been sought by taking the mean concentration for the six patients in each group at the 24 times and subjecting these values to a Mann-Whitney test.
Results
and 1505 h. Phenformin sustained release capsules (50 rag) were taken at 0835 h and 1805 h and sulphonylurea therapy was taken with the appropriate meals. During the study patients ate their normal diet and they were encouraged to remain ambulant between blood samples.
Approximately 8 ml free flowing blood was taken at each sample time: -1-2 ml for metabolite assays was mixed with ice-cold 5% (v/v) perchloric acid and refrigerated immediately; 1.5 ml was briefly centrifuged and the plasma separated immediately for measurement of non-esterified fatty acids (NEFA); the remainder was allowed to clot, separated, and stored at -20~ for subsequent hormone assay.
Glucose (hexokinase method), lactate, pyruvate, glycerol, and
Blood Glucose and Serum Insulin
The diurnal rhythm for blood glucose concentration in the two groups of patients is shown in Figure 1 . There was no significant difference for either fasting blood glucose or the diurnal rhythm between the two groups. Over the 12 h period good control of blood glucose was obtained in both groups with the exception of post-breakfast hyperglycaemia. Similarly for serum insulin there was no significant difference between the groups ( Table 2, Table   3 ). 2. Blood Lactate and Pyruvate (Fig. 2) There was no significant difference in fasting blood lactate concentration between the two groups of patients ( Table 2 ). The differences between postbreakfast and post-dinner concentrations minus the pre-prandial concentrations were greater in the patients with complications. Four patients in the group with complications had 12 h mean concentrations greater than 2 mmol/1 ( Table 3) complications all six had 12 h mean concentrations between 1 and 2 mmol/1 (Table 3 ). Over the 12 h there was a highly significant difference between the two groups (p < 0.001).
There was no significant difference between the two groups for fasting blood pyruvate concentration (Table 2 ). Over the 12 h period, however, there was a significant difference between the two groups with patients with complications having higher blood pyruvate concentrations (p < 0.01, Table 3 ). (Fig. 3) Fasting concentrations of blood total ketone bodies did not differ significantly between the two groups of patients. Over the 12 h period higher concentrations were seen in the patients with complications and this difference was statistically significant (p < 0.001). This difference was observed for both 3-hydroxybutyrate (p < 0.001, Table 3 ) and acetoacetate (p < 0.001, Table 3 ).
Blood Total Ketone Bodies

Lactate/Pyruvate (L/P) Ratio and 3-Hydroxybutyrate/Acetoacetate Ratio
Although both blood lactate and blood pyruvate were significantly elevated in the group of patients with complications, the increase in blood pyruvate concentration was relatively less than that in blood lactate concentration (Fig. 2) . The L/P ratio therefore was significantly elevated over the 12 h period in the patients with complications (p < 0.001, Table 3 ). Four of the patients with complications and two of those without, had 12 h mean L/P ratios greater than 15. Similarly, although both 3-hydroxybutyrate and acetoacetate were higher in the patients with complications, 3-hydroxybutyrate showed the greater increase. Thus over the 12 h period there was a significant difference between the groups in the 3 -hydroxybutyrate/acetoacetate ratio with the patients with complications having the higher values (p < 0.05, Table 3 ). (Fig. 3) and Alanine/Pyruvate Ratio There was no significant difference between the two groups in fasting blood alanine concentrations (Table  2 ). Over the 12 h period, however, blood alanine concentrations were significantly higher in the group of patients with complications (p < 0.001, Table 3 ).
Blood Alanine
As for the L/P ratio, blood alanine was elevated proportionately more than blood pyruvate in the group of patients with complications resulting in these patients having significantly higher alanine/ pyruvate ratios (p < 0.001, Table 3 ).
Blood Glycerol and Plasma NEFA
There was no significant difference in blood glycerol concentrations between the two groups of patients ( Table 2, Table 3 ). Similarly plasma NEFA showed no significant difference between the two groups ( Table 2, Table 3 ).
Serum Growth Hormone
There was no significant difference between fasting concentrations of HGH in the two groups (Table 2) . Over the 12 h period however patients without complications had significantly higher concentrations (p < 0.001, Table 3 ).
Biguanide Withdrawal
Two patients in the group without complications and one patient in the second group have been studied on the same sulphonylurea therapy following cessation of phenformin. All three patients showed a rise in 12 h mean blood glucose concentration although this was more marked in the patient with complications (Table 4) . Concentrations of blood lactate, pyruvate and alanine, and the lactate/pyruvate and 3-hydroxybutyrate/acetoacetate ratios were lower in all 3 patients (Table 4) .
Discussion
In the present study we have shown significantly higher circulating concentrations of lactate, pyruvate, alanine and total ketone bodies in patients with diabetic complications compared to those without complications during combined sulphonylurea and phenformin therapy. Patients without evidence of diabetic complications had concentrations of intermediary metabolites similar to those observed in patients treated by phenformin alone in a previous study [3] although we have not studied diabetics with complications treated by phenformin alone. Thus the combination of sulphonylurea and phenformin therapy does not correct the abnormalities in intermediary metabolism produced by phenformin. The more marked abnormalities in the group of patients with complications occurred despite similar blood glucose concentrations in the two groups. This does not imply, however, that the glucose lowering effect of phenformin was of similar magnitude in the two groups. It is possible that the differences between the two groups are due to inherent differences between patients who develop complications as opposed to patients without complications, although it seems more likely that impaired excretion of the drug with increased tissue concentrations results in a greater metabolic effect in the group with complications. We have previously shown that because of the relationship of plasma creatinine and creatinine clearance a normal plasma creatinine concentration may occur in patients such as these with decreased creatinine clearance [12] .
Three major mechanisms have been postulated to explain the action of biguanides. They have been shown to inhibit intestinal absorption of glucose [13] , amino acids [14] , and other nutrients [15, 16] . In this study there was no difference between the two groups in the rises in blood glucose concentration following meals. Inhibition of hepatic gluconeogenesis has been shown in animal experiments [17, 18, 19] , and recently Dietze et al [20] have reported findings consistent with inhibition of gluconeogenesis in man by phenformin. In addition, biguanides have been reported to increase peripheral utilisation of glucose [21] . Either impaired hepatic gluconeogene-sis and/or increased peripheral utilisation could explain the elevations in blood lactate, pyruvate and alanine observed.
In animal experiments the relationship between inhibition of gluconeogenesis and decreased ATP concentration or ATP/ADP ratio produced by phenformin is unclear [19] . Recently it has been shown that phenformin alters the electro-static surface potential of the mitochondrial membrane [22] which might impair transport of reducing equivalents across the membrane. As in our previous study [3] the lactate/pyruvate ratio and the 3-hydroxybutyrate/ acetoacetate ratio were elevated from normal and this was more marked in the patients with complications. These two ratios are crude indices of the cytosolic and mitochondrial redox ratios respectively and indicate that phenformin causes a more reduced state within the cell.
Attention has been drawn previously to the increases in blood total ketone body concentrations which occur in patients taking phenformin [23] . Concentrations of 3-hydroxybutyrate and acetoacetate in the patients without complications were similar to those found in patients treated by phenformin alone. Concentrations of both ketone bodies were higher in the patients with complications. Since similar concentrations of NEFA were found in the two groups of patients the difference in total ketone body concentrations is unlikely to be due to enhanced fatty acid oxidation. An alternative explanation is that phenformin, by producing a more reduced state in the cell results in an increased malate/oxaloacetate ratio and a fall in oxaloacetate concentration. Under conditions of decreased oxaloacetate availability for condensation with acetyl CoA and citrate formation, acetyl CoA is diverted to ketone body formation.
In this study we have been unable to detect any difference between the two groups of patients for blood glycerol concentration. Perfusion of isolated rat [24] and guinea pig [19] livers have shown an effect of phenformin upon uptake of glycerol by the liver, and in a previous study increased blood glycerol concentrations were found in diabetics treated with phenformin [3] . The concentrations of blood glycerol in our two groups of patients were similar to the concentrations observed in the previous study. Results from perfusions of isolated guinea pig livers with phenformin suggest that gluconeogenesis from glycerol is less sensitive to inhibition by phenformin than gluconeogenesis from lactate, pyruvate, or alanine [19] .
Finally, throughout this study we have highlighted the difference between the two groups of patients. It should be borne in mind however that in both groups the concentrations of blood lactate, pyruvate, alanine and several other intermediary metabolites are higher than those found either in normal subjects [25] or in similar patients treated only by sulphonylureas [3] . Clearly, therefore, phenformin produces these abnormalities whether used alone [3] or in combination with a sulphonylurea, while the presence of diabetic complications accentuates the abnormalities. The presence in a patient of less marked degrees of diabetic complications would presumably result in concentrations of metabolites intermediate between our two groups of patients but clearly abnormal.
